USA-based Amgen has been issued with subpoenas from the US Attorney's offices in New York and Washington, seeking documents related to two, as yet unidentified, products. Meantime, Amgen said that the Sheet Metal Workers National Health Fund had, under California's unfair competition law, filed a law suit against it, alleging that the company had engaged in an "anti-competitive tying arrangement and pricing scheme," regarding Neupogen (filgrastim), Neulasta (pegfilgrastim) and Aranesp (darbepoetin alfa).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze